Let’s Chat: Patient Submissions and Discussion

AS PART OF PATIENT ADVOCACY, SAVE YOUR SKIN FOUNDATION IS ONE OF THE SELECT PATIENT ADVOCACY ORGANIZATIONS THAT IS APPROVED TO SUBMIT TREATMENT RECOMMENDATIONS TO THE CADTH COMMON DRUG REVIEW (CDR), TO PCODR (PAN-CANADIAN ONCOLOGY DRUG REVIEW) AND INESSS (Institut national d’excellence en santé et en services sociaux)  FROM THE PATIENT PERSPECTIVE. Click HERE to learn more about CADTH and INESSS processes.

Thank you to all patients and their caregivers who share their experience and feedback in our anonymous online surveys regarding treatments they have had – this feedback goes directly to decision-makers in the drug approval process across Canada.   Watch our social media channels for updates on current recommendations and approvals.

March 30, 2021: Health Canada has just approved BRAFTOVI (encorafenib) to be used in combination with MEKTOVI (binimetinib), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.  Click HERE to read more 

We hope that every province and territory will take swift steps to list this drug on their public formularies in order to make this therapy available to patients.

Save Your Skin Foundation is pleased to have submitted patient feedback on the targeted therapy Braftovi™ in combination with Mektovi®, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. SYSF also supported Health Care Providers with their Clinician Input submissions for this treatment.

Great news for Squamous Cell Carcinoma patients! Updates:

August 2021: All provinces have listed with the exception of P.E.I. and Newfoundland & Labrador

February 3, 2021: Libtayo^TM Funded in Ontario and British Columbia

December 15, 2020: Libtayo^TM Funded in Quebec

December 1, 2020: Libtayo^TM Funded in Manitoba and Saskatchewan

Save Your Skin Foundation Applauds the pan-Canadian Oncology Drug Review recommendation for Provincial Reimbursement of Libtayo^TM for the treatment of Advanced Cutaneous Squamous Cell Carcinoma (cSCC) TORONTO, ONTARIO, January 15, 2020 – Read More

An up-to-date list of available treatments can be found on the Canadian Agency for Drugs and Technologies in Health (CADTH) website’s Provincial drug formulary database, which can be accessed HERE, and for Quebec, at the INESSS site, HERE.

Share and chat with other patients, family members and others concerned about melanoma and skin cancer through one of our social media channels